1、 Overview of peptide medicine industry
Polypeptides are a class of compounds formed by multiple amino acids linked by peptide bonds. They are usually composed of 10-100 amino acid molecules. Their connection mode is the same as that of proteins, and the relative molecular weight is less than 10000.
Polypeptides widely exist in organisms, and tens of thousands of polypeptides have been found in organisms. They widely participate in and regulate the functional activities of various systems, organs, tissues and cells, and play an important role in life activities.
In recent years, peptide drugs synthesized by modern biotechnology have become one of the hot spots in drug research and development. Because of its wide indications, high safety and significant curative effect, it has been widely used in the prevention, diagnosis and treatment of cancer, hepatitis, diabetes, AIDS and other diseases, and has broad development prospects.
Polypeptide drugs are mainly derived from endogenous polypeptides or other natural polypeptides. Their structures are clear and their mechanisms of action are clear. The level of quality control is close to that of traditional small molecular chemical drugs, while the activity of peptide drugs is close to that of protein drugs Tumor, infection, etc.
At present, the main preparation methods of peptide drugs in China are chemical synthesis, gene recombination and extraction. Biological peptide extraction technology has been gradually replaced by chemical synthesis or gene recombination technology.
Main preparation methods of polypeptide drugs
2、 Analysis on the development status of polypeptide drug industry
In recent years, the global peptide drug market is on the rise, and peptide drugs have become an important direction of new drug research and development at home and abroad.
According to the data, as of May 2019, there were 1153 kinds of peptide synthetic drugs in the world, and 198 kinds of polypeptide drugs were listed in 2018, among which the anti-tumor field was the largest, followed by reproductive and urinary system and sex hormones, cardiovascular system drugs and anti infective drugs.
Related report: report on market depth analysis and development prospect forecast of China’s polypeptide drug industry from 2020 to 2025 issued by China Economic Industry Research Institute
Compared with the developed countries and regions, there is still a big gap in the field of peptide drugs in China, and the product structure is also different. Among them, the products of immune enhancement are the majority, while the products for cancer, diabetes and rare diseases account for a relatively small proportion.
The market is not mature and far from saturated. According to the data, the market scale of peptide drugs in China reached 63.05 billion yuan in 2017. In 2018, the market scale of peptide drugs in China was 75.66 billion yuan.
3、 Prospect of peptide drug market
There are a large number of cancer and chronic disease patients in China due to the large population base and the aggravation of aging. China’s medium and long term plan for chronic disease prevention and control (2017-2025) proposes that the number of patients with hypertension and diabetes in China will increase to 110 million and 40 million by 2025.
It is expected that the demand for peptide drugs will continue to expand in the future, and there is still room for substantial growth of peptide drugs.
Although great progress has been made in the research and development of peptide drugs, peptide drugs are still facing various challenges.
The development of peptide drugs is limited by the high investment and high risk, and the problems of synthesis technology, production process and product purity lead to the product quality not meeting the requirements or the high cost.
In addition, with the rapid development of modern technology and equipment, the cost of polypeptide production has dropped significantly, and peptide drugs have entered the golden stage of development. In the future, polypeptide chemistry, recombinant protein production, enzymatic synthesis, bio organic chemistry and other multi-disciplinary fields may have more cross and integration, so as to improve efficiency and promote large-scale production.
Long acting peptide or sustained-release system can maintain or improve the activity of a smaller amount of peptide drugs in the human body for a longer time.
The huge competition of peptide companies in the peptide market will inevitably change, and the market competition will be intensified.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……